Figure 4.

Molecular predictors of OS. Kaplan-Meier survival blots stratified by adverse cytogenetics (CG) vs not (A), NRAS/KRAS mutation vs not (B), TP53 mutation vs not (C), SF3B1 mutation present vs not (D), EZH2 mutation present vs not (E), IDH1/2 or NPM1 mutation present vs not (F), STAG2 mutation present vs not (G), and DNMT3A mutation present vs not and previous HMA received vs no previous HMA received (H). (I) Multivariable analysis of clinical and genetic predictors of OS. Aza, azacytidine; Dec, decitabine; LDAC, low-dose cytrabine; Mut, mutation; ven, venetoclax.